3D Printing Entrepreneur
According to REMET Inc.,” has its own process & engineering department and complex machine park which includes large-size machining equipment that allows us to produce highly processed steel structures.”
According to 3D Lab,” is a company with over 10 years of experience and an established position in the 3D printing industry. Its main focus is the delivery and maintenance of additive manufacturing devices. 3D Lab has established a leading position in the field of professional and production-oriented AM systems in the domestic market. It also provides research and development services, commercial 3D printing, and parameter optimization of metal powders melting processes. A wide scope of cooperation with leading scientific centers allows 3D Lab to offer professional, comprehensive services, including preparation of material data sheets for the produced materials.”
According to Relativity Space is a private American aerospace manufacturer company headquartered in Los Angeles, California, “Relativity Space was founded on the idea that Blue Origin and SpaceX were not doing enough to use 3D printing as part of rocket manufacturing. Relativity plans to 3D print an entire launch vehicle they call Terran 1. The extensive use of 3D printing has allowed the company to iterate designs quickly, use less tooling and human labor. In March 2018, Relativity Space signed a 20-year lease at the John C. Stennis Space Center, a NASA rocket testing facility, to test engine components and eventually test full-scale Aeon 1 rocket engines.
The company says it will launch its first rocket named Terran 1 from the site in 2020. Relativity plans to start commercial launch service by early 2021.”
According to Ken Jin, co-founder, and chief technology officer of Meditool, “Meditool is one of the pioneers in developing 3D printed PEEK medical implants. Evonik has been our trusted partner in materials supply. The venture investment will be an extra boost to our endeavor to bring innovative solutions to patients and surgeons in China and the rest of the world.”
Evonik’s venture capital arm has already invested in two funds in China and with Meditool, it now has its first direct investment. Co-investors in Meditool include ZN Ventures, Morningside Ventures, and Puhua Capital.
Physna: Compare thousands of 3D models in seconds,
According to Physna’s CEO Paul Powers and Glenn Warner, “Through revolutionary artificial intelligence, Physna uses advanced algorithms to dissect and analyze 3D objects in the blink of an eye.
Many companies have collectively spent billions of dollars on this problem. The reason that Physna is the first to actually fix it is that we used a fundamentally different type of technology.
Compare your IP with others in seconds, ensuring that you’re using the correct models and nobody else is using your designs. Promptly determine if a 3D object matches your standards, allowing you to get to market quicker. Find any 3D object in seconds, old or new, helping to keep department and operation costs to a minimum. Compare any two models instantly and see exactly how much they match with total accuracy and reliability. We call those facets. Everything in nature can be broken down into triangles. We basically analyze the relationship of facets to each other and to the surrounding environment.”
According to Dr. Alex Morgan, Principal at Khosla Ventures and Dr. Melanie Matheu, Prellis Biologics’ co-founder and CEO, “Regenerative medicine has made enormous leaps in recent decades. However, to create complete organs, we need to build higher-order structures like the vascular system. Prellis’ optical technology provides the scaffolding necessary to engineer these larger masses of tissues. With our investment in Prellis, we’re supporting an initiative that will ultimately produce a functioning lobe of the lung, or even a kidney, to be used in addressing an enormous unmet global need.
The human tissue engineering is the ability to build complex tissues with working vascular systems. The future of regenerative medicine revolves around harnessing the power of our own cells as therapeutics and building the tissues to keep them alive. Khosla Ventures is the perfect investor to support our merging of deep tech and cutting-edge regenerative medicine. With this technology in hand, we can begin to ask questions about real 3D cell biology that have never been asked before.”